Get the Stockscreener App
47.70
9.55%
4.16
After Hours:
47.05
-0.65
-1.36%
Soleno Therapeutics Inc stock is traded at $47.70, with a volume of 3.94M.
It is up +9.55% in the last 24 hours and down -23.20% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$43.54
Open:
$43.43
24h Volume:
3.94M
Relative Volume:
1.91
Market Cap:
$2.54B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-15.92
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-28.98%
1M Performance:
-23.20%
6M Performance:
-36.11%
1Y Performance:
-16.48%
1-Day Range:
$41.80
$48.82
1-Week Range:
$41.80
$69.99
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
47.70 | 2.34B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Analyzing net buyer seller activity in Soleno Therapeutics Inc.Earnings Miss & Real-Time Sentiment Analysis - newser.com
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - PR Newswire
Real time social sentiment graph for Soleno Therapeutics Inc.Quarterly Performance Summary & Community Verified Watchlist Alerts - newser.com
Full technical analysis of Soleno Therapeutics Inc. stock2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Will Soleno Therapeutics Inc. outperform the marketMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q3 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid - GlobeNewswire
Has Soleno Therapeutics Inc. formed a bullish divergencePortfolio Performance Summary & Low Risk Entry Point Guides - newser.com
Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings - Insider Monkey
Published on: 2025-11-06 09:34:24 - newser.com
How moving averages guide Soleno Therapeutics Inc. tradingJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Can Soleno Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com
Is Soleno Therapeutics Inc. stock a smart buy before Fed meetingBond Market & Fast Entry and Exit Trade Plans - newser.com
Will Soleno Therapeutics Inc. stock outperform tech sector in 2025 - newser.com
Is Soleno Therapeutics Inc. (6XC) stock good for long term investingWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Soleno Therapeutics (SLNO): Losses Accelerate 43.6% Annually, Challenging Bullish Profitability Narrative - Yahoo Finance
What makes Soleno Therapeutics Inc. stock attractive to growth funds2025 Earnings Surprises & Weekly Watchlist for Consistent Profits - fcp.pa.gov.br
Will Soleno Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Rallies & Long Hold Capital Preservation Plans - newser.com
Soleno plunges despite Q3 beat as demand for Vykat XR cools - MSN
Is Soleno Therapeutics Inc. stock a bargain at current levelsQuarterly Profit Review & Short-Term High Return Ideas - newser.com
Will Soleno Therapeutics Inc. (6XC) stock outperform small cap peersJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - newser.com
Soleno Therapeutics (NASDAQ:SLNO) Posts Quarterly Earnings Results, Beats Expectations By $0.39 EPS - MarketBeat
Can Soleno Therapeutics Inc. stock maintain operating margins2025 Market Overview & Precise Entry and Exit Recommendations - fcp.pa.gov.br
Soleno signals continued VYKAT XR market growth with net revenue doubling to $66M as European expansion advances - MSN
Soleno stock plunges despite Q3 beat (SLNO:NASDAQ) - Seeking Alpha
Oversold Conditions For Soleno Therapeutics (SLNO) - Nasdaq
Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent - BioPharma Dive
Wells Fargo Lowers Price Target for SLNO, Maintains Overweight R - GuruFocus
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
What data driven models say about Soleno Therapeutics Inc.’s futureWeekly Trading Summary & Daily Growth Stock Investment Tips - newser.com
Is Soleno Therapeutics Inc. a candidate for recovery playJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
Published on: 2025-11-05 03:34:22 - newser.com
Soleno Therapeutics Swings to Q3 Profit; Shares Fall After-Hours - MarketScreener
Transcript : Soleno Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ... By GuruFocus - Investing.com Canada
How Soleno Therapeutics Inc. stock benefits from strong dollarJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Strategies to average down on Soleno Therapeutics Inc.Earnings Overview Summary & Safe Entry Point Identification - newser.com
Soleno Therapeutics Achieves Profitability with VYKAT XR Launch - TipRanks
Earnings call transcript: Soleno Therapeutics Q3 2025 earnings beat expectations - Investing.com
Soleno Therapeutics tumbles despite Q3 earnings, revenue beat By Investing.com - Investing.com UK
Soleno Therapeutics Turns A Profit Thanks To VYKAT XR - Finimize
Soleno Therapeutics tumbles despite Q3 earnings, revenue beat - Investing.com
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q3 Revenue $66.0M, vs. FactSet Est of $48.1M - MarketScreener
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR - The Manila Times
Soleno Therapeutics (NASDAQ: SLNO) posts $66M revenue; $26M net income, profitable quarter - Stock Titan
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jul 01 '25 |
Sale |
82.76 |
3,830 |
316,971 |
13,206 |
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):